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Abstract
P-glycoprotein (P-gp) is an active member of the ATP Binding Cassette (ABC) 
protein subfamily which effluxes a wide range of therapeutic drugs out of the cells 
commonly known as multidrug resistance. But its protective action towards the 
normal cells and efflux of the toxic and foreign substances is remarkable. Hence the 
efflux of the P-gp is a crucial step to overcome for the success of the therapy and in 
the drug discovery process. Modification of the action of the P-gp through various 
inducers, inhibitors or the genetic polymorphism is the commonly used methods. 
When it comes to the inhibitor part the natural inhibitors use is more safe and 
economical as compared to the synthetic ones. Here we review at the mechanism 
of action and the pharmacokinetic profile of P-gp, how the P-gp engaged in the 
Multidrug resistance, the strategy to overcome from its action by using natural 
inhibitors and formulation perspectives.
Keywords: P-glycoprotein, multidrug resistance, mechanism of action, 
pharmacokinetics, P-gp inhibitors, natural inhibitors
1. Introduction
Reduce in the remedial rate of most of the diseases and the decline in the 
therapeutic efficacy of most of the anti-neoplastic and anticancer drugs is due to 
the phenomena called drug resistance [1]. The main ambiguity to be found out 
to increase the efficacy of the drugs is to overcome this phenomenon. The drug 
resistance is not observed to a single chemotherapeutic drug but to a broad range 
of structurally and functionally different drugs. The exposure to a single therapy 
for a long time and the recurring use of the medication leads to drug resistance will 
leads to decrease in the therapeutic efficacy of the drugs. Even if the dose is altered 
there would not produce any momentous changes in this phenomena [2]. When 
the human acquired resistance to the drugs it is termed as drug tolerance. This was 
usually seen of two type’s pharmacokinetic drug tolerance and pharmacodynamic 
drug tolerance.
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2. Metabolic or pharmacokinetic tolerance
Followed by the entry of the drug in our body with the time it gets absorbed into 
the bloodstream, which is then carried out and distributed to various other sites, 
additionally gets disintegrated into various segments and eventually gets excreted 
from the body. All these factors determine the potency, side effects and duration 
of action of the drugs. The major reason for the pharmacokinetic tolerance is when 
the drug fails to maintain its minimum therapeutic concentration at the target site. 
Where, in this case the enzymatic action of cytochrome P450 (CYP450) produces 
the effect. This type of tolerance is mainly determined with the oral dosage form 
which produces first pass metabolism. Induction of the enzymes are the major 
reason behind the drug resistance which is further accompanied with various other 
factors which is further disused in this chapter in detail.
3. Pharmacodynamic tolerance
When the cellular feedback to a substrate is concentrated the development of 
the pharmacodynamic tolerance eventually occurs. The principle reason behind 
pharmacodynamic tolerance is when the therapeutic concentration of the substrate 
to the binding receptors reaches above the maximum therapeutic concentration 
which eventually results in the desensitisation of the receptors [3]. Other possibili-
ties include the decline in the receptor density which is mainly associated with 
the receptor agonist and the modification in the action of the possible firing rate. 
Generally the drug resistance will occur subsequent to the incessant exposure to the 
drug, but instant tolerances were also observed in rare cases [4].
4. Factors responsible for drug resistance
There are a variety of drug resistance usually seen such as anticancer resistance, 
anti-human immunodeficiency virus (HIV) drug resistance, antibiotic resistance, 
anti-tubercular drug resistance, anti-malarial drug resistance and anti-microbial 
drug resistance. The most part of the drug resistance is caused by MDR proteins, 
where in this P-gp (P-glycoprotein) involves in producing a major aspect in reduc-
ing the drug efficacy in most of the treatment. P-gp, which is a trans-membrane 
(TM) glycoprotein physiologically, expressed in the parts of the body such as 
kidney, liver, pancreas, colon and jejunum [5], it also expresses its role eventually in 
the brain capillary epithelial cells. The core function of P-gp is to safeguard the cells 
and restrict the entry of xenobiotics and toxic substances. But its action is over-
expressed in the diseased cells by restricting the entry of the drugs hence its action 
should be inhibited in such cases for the success in the therapy.
5. Transporters and its family
P-gp is an efflux protein system associated with the ATP binding cassette 
(ABC) sub-family B membrane or Multi-drug resistance 1 (MDR1) or cluster of 
differentiation 243 which belong to ABCB (MDR) super family of ABC transporter 
[6]. ABC gene indicates the leading family of TM protein, originated mainly in the 
intercellular membrane or the plasma membrane. By using the energy from the 
ATP the transport mechanism across the cell membrane is initiated. In humans 
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around 49 ABC transporters are observed [7], where MDR1A, MDR1B and MDR2 
[8] are usually identified in animals and MDR1 and MDR3 [9] which belong to the 
P-gp gene subfamily is mostly seen in humans. Where MDR1 (P-gp) is widely seen 
all over the body and efflux a wide range of drugs over the plasma membrane and 
MDR3 (P-gp) is predominantly observed in the liver, canalicular membrane of the 
hepatocytes and is accountable for the phosphatidylcholine secretion into the bile 
[10]. Even though the action of MDR3 or P-gp in the efflux transport mechanism is 
observed, their direct action in drug resistance is restricted.
The efflux action exhibited by P-gp is having a greater importance since it can 
protect our body from the entry of the toxins and xenobiotics into the cells mainly 
to brain, placenta and gonads and eliminating the waste products through the urine 
[11], by facilitating the energy driven with the ATP hydrolysis the amphipathic 
drugs are mainly eliminated by the efflux action of the P-gp.
P-gp role is mainly observed in the body parts such as kidney, intestine, liver 
[12], testis and brain [13]. The entry of the xenobiotics into the blood capillaries 
are mainly minimised by the localised action of P-gp in the luminal membrane of 
the epithelial cells [14]. Over-expression of the P-gp is the foremost reason behind 
the failure of the chemotherapy and other treatment strategies where nowadays the 
researchers are mainly focussed to overcome with this issue. The studies related to 
the action exhibited by the P-gp are performed in mice, rats [15] and in humans [16]. 
The substrates which merge with P-gp have unrelated frameworks. The compounds 
transported by P-gp are considered as substrates, while the compounds that prohibit 
the role of P-gp are considered as inhibitors.
P-gp was identified first in 1976 in Chinese hamster ovary cells, where it was 
obtained to demonstrate anticancer resistance [17]. The research data proved that 
the P-gp have the ability to acquire resistance to the cytotoxic drugs. They also 
proved that verapamil was helpful to measure the function of the P-gp by using 
positron emission tomography [18]. P-gp is used for differentiating the transitional 
B-cells from the native B-cells. Rhodamine 123 and Mito Tracker Dyes are also used 
for this purpose [19].
6. Cellular localisation
The expression of P-gp is recurrently found predominant in the cancer cells, 
causing MDR by efflux of lypophilic drug from the cell. P-gp is observed to be over-
expressed in renal, colon and adrenal carcinoma, not often in germ cell tumour and 
lungs even certain in gastric carcinoma, undetectable in breast and endometrial car-
cinomas. In the normal cells the concentration of the P-gp and its expression is found 
to be low, but certain cell types like colon, kidney, liver, jejunum and pancreas shows 
a higher expression of P-gp. While in liver, the broad distribution of P-gp is found on 
the apical surface of epithelial cells and biliary canalicular front in the small biliary 
ductules [20]. When it appears in case of pancreas, P-gp exclusively found of the api-
cal surface of epithelial cells of the small ductules. In Kidney the presence of the P-gp 
is exclusively found on the apical surface of the epithelial cells of the proximal tubules 
[5]. P-gp expression shows an identical expression in the apical surface of superficial 
columnar epithelial cells of both jejunum and colon. Where, the expression of P-gp is 
mostly seen in the surface of cortex and medulla cells in the adrenal glands. Its pres-
ence is found out with both secretary and excretory action in the specialised epithelial 
cells, placental trophoblast [21] and endothelial cells of capillary cells at blood-tissue 
barrier sites. Its presence is also found in the epithelial cells of bronchi and gastroin-
testinal tract, prostate gland, salivary glands and sebaceous gland of the skin.
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The research reports proved the occurrence of P-gp in the human fetus is 
with the significance in the regular performance of various organs in the initial 
stage of embryo development [22]. The evidential reports from the research work 
conducted in the tissues of rodent and humans [23] came to a conclusion that the 
expression of the P-gp in the normal tissues are much lower than compared to that 
at the epithelial cell lining of small Intestine, colon, pancreatic duct, proximal 
tubules of kidney, bile ducts and adrenal gland [24]. P-gp over-expression is also 
observed in the secretary epithelial cells in the endothelium of the pregnant woman 
and also in the placenta for protecting the fetus [25].
7. Kinetics of P-gp
7.1 Absorption
The major reason behind the multidrug resistance in the cancer cells is the action 
exhibited by P-gp. P-gp transports a wide range of structurally and functionally 
different cytotoxic compound out of the cell by using the energy driven from 
ATP. Altering in this property caused by P-gp is a vital approach for overcoming 
the MDR part and to increase the therapeutic efficacy during the treatment. The 
incorporation of the P-gp inhibitors with the resistant drugs can be helpful towards 
suppress the expression of the P-gp. This situation of resistance part not only 
happens with the chemotherapeutic drugs but also for the treatment strategy used 
for other conditions also [26]. The over-expression of P-gp in the diseased cells as 
compared to that of the normal cells is the major reason behind this phenomenon. 
Research work carried out came with a conclusion that P-gp is the major cause for 
the antibiotics resistance part also. P-gp trims the overall permeability of the drug to 
reach the target site by reducing the minimal therapeutic concentration level [27].
7.2 Distribution
P-gp acts as an integral element in the distribution of the drugs. Its action is 
noticed in the blood brain barrier and also the placental barrier. It can accomplish 
its effect on the distribution of various therapeutic agents also reduce its activation 
in the body. The role of P-gp in the brain turned into a point where it resists the 
entry of the neuro-toxic drugs into the brain and hence sustains the penetration of 
central nervous system (CNS) agent delivery in the brain [28]. A modulator is in 
need to inhibit the action of P-gp for improving the efficacy of CNS drugs to the 
target site including for the Parkinson’s and Alzheimer’s disease. When it comes 
towards P-gp inhibition the P-gp also protect the fetus from the entry of the foreign 
bodies and toxic substances through the placenta [29, 30]. Hence by considering 
these aspects the inhibition of the P-gp is to be made in a careful manner by not 
altering the protective mechanism in the normal cells [31].
7.3 Metabolism
The enzymatic activity of CYP3A4 and the efflux mechanism by P-gp together 
play the role for the decreased therapeutic efficacy and bioavailability of the drugs 
administered through the oral route. These are major defence system in intestine 
which acts as a protective barrier from the entry of the toxic substances and the 
xenobiotics. These proteins are mainly over-expressed in enterocytes and hepato-
cytes and also establish its role in first pass metabolism of the drugs.
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For supporting this statement piperine can be taken as an example. The flavo-
noid piperine is obtained from black pepper. It have the ability to act as a natural 
inhibitor of P-gp and CYP34A when and can increase the therapeutic efficacy of the 
drugs when co-administered [32]. The dose of the piperine administered should be 
ideal and reaches the minimum therapeutic concentration to produce this effect. 
Another example is the action exhibited by grape fruit juice. When grape fruit juice 
and saquinavir is co-administered, the therapeutic concentration of the parent drug 
can be increased when administered during oral route.
8. Elimination
8.1 Renal excretion
The process of glomerular filtration, tubular secretion and reabsorption involve 
in the mechanism of renal excretion. P-gp involved in the efflux of the xenobiotics 
and the waste materials from our body via renal excretion, results in reduced level 
of the therapeutic drug in the blood plasma. This can also be altered by incorpo-
rating the flavonoids with the therapeutic agents. When digoxin a flavonoid and 
Cyclosporine A is co-administered, Cyclosporine will increase the concentration 
of digoxin in the plasma by decreasing tubular secretion and glomerular secreation 
rate [33, 34]. Comparable results are obtained when itraconazole and cimetidine is 
coadministered [35].
8.2 Biliary excreation
The excretion of the drugs by the influence of the P-gp can also be altered by 
using the natural P-gp inhibitors. Quercetin, a natural inhibitor of P-gp can add on 
to the therapeutic concentration of a wide range of drugs in the target site when co-
administered. In turn the therapeutic agents such as Azithromycin, erythromycin, 
cyclosporine A and doxorubicin have an inhibitory action on biliary excretion of 
drugs mediated by P-gp [36].
8.3 Antimicrobial drug resistant mechanism
The mechanism by which the antimicrobial drugs acquiring resistance to the 
microorganisms are as follows:
1. Drug inactivation or modification: enzymatic deactivation of pencillin G and 
the synthesis of β-lactamase in the penicillin resistant bacteria.
2. Verification in target site: the shifting of the pencillin binding site from PBP to 
MRSA in the bacteria resistant to the penicillin drug.
3. Metabolic pathway modification: For example, the para-aminobenzoic acid 
path is not necessary for the sulfonamide resistant bacteria which are the 
extensive predecessor for the combination of nucleic acid and folic acid, as an 
alternative of like mammalian cells they employ preformed folic acid.
4. Intercellular drug concentration diminution: accumulation of the drugs within 
the cells is declined by diminishing the drug efflux and drug permeability 
across the cell surface.
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8.4 P-gp role in drug resistance
P-gp has a leading aspect in reducing the bioavailability and distribution of the 
drugs, where P-gp is over-expressed in intestinal region which act as a substrate to 
P-gp and reduces its absorption pathway. Hence the therapeutic level of the drugs 
and the bioavailability of the drugs are not accomplished. On the other hand if the 
P-gp expression is abscessed then the concentration of the drug in the plasma will 
reach to supra-therapeutic concentration leading to toxicity related issues [9].
The substrate infiltrate into the P-gp all the way through the protein cytoplasmic 
side or through the inner leaflet of the membrane. ATP attitudes to the cytoplasmic 
side of P-gp, pursue with its binding, ATP hydrolysis activates which modify the 
substrate to be efflux form the cell. The substrate excretion occurs followed with the 
release of the phosphate from the ATP molecule. A novel molecule of ATP attach to 
the secondary ATP binding site when adenosine diphosphate (ADP) is discharged. 
This process will proceed with the hydrolysis and discharge of ADP and a phosphate 
molecule reset the protein.
8.5 Substrate for P-gp
P-gp transports a broad range of substrates which are structurally and function-
ally different from each other. P-gp substrate mainly appear to be lypophilic and 
amphipathic in nature [37, 38]. For altering the functions of P-gp its inhibitors are 
mostly generated. The mechanism of action is either by competition with the drug 
binding sites without hindering the action of ATP hydrolysis of by blocking the ATP 
hydrolysis process [39]. Recently allosteric mechanism for P-gp mediated transport 
also added with the other two mechanisms [40]. P-gp substrates are attached with 
the protein molecule before getting attached or moved to the extracellular mem-
brane leaflets.
8.6 P-gp inhibitors
The reports from the research work proven that the P-gp has the ability to 
interact with more than 20 substrates or the modulators. Some of the substrates 
which are easily transported by P-gp include anthracycline, vinca alkaloids and 
fluorescent lipids. This binding action of the modulators such as cyclosporine 
and verapamil are employed for altering the P-gp activity for the chemotherapy. 
The high flexible and the low specific nature of the P-gp binding pockets could be 
employed for overcoming the MDR related issues during the chemotherapy [41]. 
The Classification of the P-gp inhibitors is mainly based on its specificity, affinity 
and the toxicity. The classification and the division of the inhibitors are mentioned 
in Table 1.
8.7 First generation inhibitors
The inhibitors belonging to this generation are pharmacologically active in 
nature and are used in specific treatment. Some of them are reserpine, verapamil, 
cyclosporine A, yohimbine, quinidine, toremifene and tomoxifene. When we are 
taking the example of leukaemia cells, the resistance could be inverted by using 
verapamil [42] for producing an effective action high dose of the drug is given to the 
patient, results in cardiovascular toxicity [43]. Hence these inhibitors are replaced 
with the second generation inhibitors because of their less therapeutic efficacy.
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8.8 Second generation inhibitor
The substrates coming in this generation inhibitors are pharmacologically 
inactive in nature but produce its action on P-gp. This generation inhibitors are 
developed by structurally modifying the first generation inhibitors for obtaining 
high specificity, low toxicity and potency. Examples for this generation inhibitors 
include doxverapamil [44], valspodar (PSC 833) [45], biricodar citrate (VX710) 
[46], dofequidarfumerate and dexniguldipine. Non immunosuppressant analogues 
of dox verapamil and cyclosporine A are mainly included in this category. PSC 833 
which is the most frequently used inhibitor exhibit 5–10 times more potency as 
compared to that of cyclosporine A [47]. On the other these inhibitors have greater 
affinity and inhibitory activity towards the ABC transporters and CYPA4 enzymes.
8.9 Third generation inhibitor
To overcome the problems associated with the first and second generation inhib-
itors, the third generation inhibitors are generally developed. The main advantage 
of using the third generation inhibitors are their less toxic effect as compared to that 
of the first two generation inhibitors and their specificity and effectiveness towards 
the P-gp. They are found with no pharmacological interaction. They do not possess 
any kind of pharmacological interaction with the chemotherapeutic agents and 
found to be 200 times more potent than first two generation inhibitors. Examples 
include Zosuquidar (LY335979), [48] Tariquidar (XR9576), Laniquidar (R101933), 
[49] Elacridar (F12091), ONT-093, [50] Mitotane (NSC- 38721), [51] annamycin, 
[52] HM30181,R10933, [53] HM30181, Biricodar. From the 3D QSAR and QSAR 
activities it is reported that the structure of the inhibitors are mainly responsible to 
produce the inhibitory activities. Studies reported that the heterocyclic ring of the 
tariquidar near to the antranilamide ring is responsible to produce the inhibitory 
activity. But the recent studies reported that tariquidar is having both substrate as 
well as inhibitory activity on P-gp [54, 55].
8.10 Fourth generation- natural inhibitors
Owing the toxicity issues and the restricted therapeutic caused with the 
synthetic inhibitors, the natural inhibitors are mainly developed which includes 
the dietary supplements also. The natural compounds and the food extracts 
are revealed with an effect on P-gp to reverse MDR and also exhibit anticancer 
property.
Generations Examples
First generation 
inhibitors
Verapamil, cyclosporine A, reserpine, quinidine, yohimbine, tamoxifen, and 
toremifene
Second generation 
inhibitors
Doxverapamil, valspodar, biricodar citrate, dexniguldipine, and dofequidar 
fumerate
Third generation 
inhibitors
Tariquidar, zosuquidr, laniquidar, elacridar, mitotane, annamycin, biricodar, 
ONT-093, R10933, and HM30181
Natural inhibitors Curcumin, piperine, capsaicin, [6]-gingerol, carnosic acid, limonin, quercetin, 
β-carotene, leutiolin, and anthocynine
Table 1. 
Generation of inhibitors with examples.
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8.11 Spices
From the ancient period itself the use of the spices are predominant as preservative 
and colouring agents. The phytochemicals constituent in spices are studied for the cure 
of various ailments and for the management and reversal of MDR caused by P-gp [56].
8.12 Curcumin
Curcumin is used as anti-oxidant, anti-inflammatory agent, anti-infective and 
anticancer agent [57]. It also exhibits an additional use of reversing the MDR caused by 
P-gp. It procure this action by acting on P13K/Akt/NF-kB [58] pathway in L1210 MDR 
leukaemia cells in the mice model. In 2008 Choi et al came with a conclusion that the 
combination of curcumin and Adriamycin can overcome the MDR effect caused by 
P-gp by studying with the western blotting results [59]. Mucoadhesive microemulsion 
loaded with curcumin has the ability for brain targeting through intranasal route [60].
8.13 Piperine
Piperine is the alkaloid constituent present in a larger proportion in black 
pepper, which is consumed by the population all over the world and added in their 
diet. Piperine was found with the activity on altering the MDR by inhibiting ABC 
transporters [61].
8.14 Capsaicin
Capsaicin is found abundant in red chilli, exhibit anticancer and inhibitory 
activity on P-gp. It potentiates anticancer activity of vinblastine by modulating 
P-gp. It has the ability to act on β-catanin and NF-KB pathways [62].
8.15 [6]-Gingerol
Ginger is constituted with a major polychemical compound [6]-Gingerol, which 
add on its spicy taste. It also inhibits β-catanin and NF-KB pathways like the action 
exhibited by capsaicin, but the actual mechanism of action is still not known [63].
8.16 Carnosic acid
Carnosic acid is the major phenolic constituent found in the leaves of rosemary. 
Carcinoic acid can act as a substrate to P-gp by stimulating the ATP activity by 
competitively binding with the ATP binding site [64].
8.17 Procyanidine
This compound composes a major constituent in tea leaves and grape seeds. It 
exhibits both chemopreventive activity and also antiproliferative effect [65]. It can 
inhibit NF-KB and translocate YB-1 into the nucleus through dephosphorylation of 
ERK1/2 and AKT [66].
8.18 Limonin
The citrus fruits are constituted higher with this crystalline compound. It acts 
as a P-gp inhibitor in leukaemia, melanoma and colon cancer cell lines. It elevates 
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the accumulation of the Rhodamine 123 and doxorubicin inside the cells. When 
administered in a concentration of 20 μm it has the ability to increase the anticancer 
activity of the doxorubicin when studied with CED/ADR5000 Caco-2 and leukae-
mia cell lines [67].
8.19 Quercetin
Quercetin is the constituent found in higher amount in onion and apple. From 
the experimental report it is found that Quercetin exhibit chemotherapeutic and 
P-gp inhibition activity. On the addition of concentration of 0.7 μm, it enhances the 
anticancer activity of doxorubicin when studies in MCF-07 cell lines [68].
8.20 β- carotene
β- Carotene is abundantly found in vegetables and fruits [69, 70] and is the 
precursor of Vitamin A [69]. When studied with Caco-2 cell lines it has the ability 
to efficacy of etoposide, doxorubicin and 5-Fluorouracil and even can manage the 
P-gp transport activity.
8.21 Strategies to overcome MDR
Various novel approaches were established for the inhibition of MDR in the 
diseased cell lines, which includes biological, physical and chemical methods as 
well as ribonucleic acid (RNA), interference, micro RNA and Nanotechologies 
[71]. MicroRNAs are the undersized non-coding RNAs are normally not syn-
chronised in the cancer cells; with the modification in the miRNA they have 
the ability to up regulate the MDR part. To alter the expression of P-gp various 
sequence of miRNAs such as miR-296, miR-27a, miR-298, miR-451 and miR-1253 
were resolved, and there were evaluated in esophageal and breast cancer cell 
lines [72–74].
8.22 Monoclonal antibodies
In the early 1980s two monoclonal antibodies MRK-16 and MRK-17 were 
discovered to alter the resistance part developed by P-gp in both in vitro and in vivo 
studies [75]. MRK-16 was proven with their ability to inhibit the efflux of the drugs 
actinomycin-D and vincristine where the MRK-17 was proven with their ability to 
inhibit the MDR cell proliferation. The enhancement in the anticancer activity can 
be achieved by conjugating the monoclonal antibodies with the P-gp inhibitors. 
Euhertner Roninson developed a monoclonal antibody UIC2 from the mouse which 
has the ability to bind with the extracellular parts of the P-gp. In turn it has the abil-
ity to decrease the efflux of P-gp substrates which in turn increases the cytotoxicity 
of P-gp substrates [76].
8.23 Non substrate development
The MDR in cancer cells are towards a broad spectrum of anticancer drugs, 
hence there is a need to develop a new anticancer drug which have less predictable 
by the ABC transporter family proteins. Hence a new strategy is followed where 
the structural modification or the conjugation is made for the discovery of the new 
molecule which is less familiar to the P-gp as a substrate and which are structurally 
similar to the compounds which act as P-gp inhibitors.
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8.24 MDR and nanotechnology
Nanoparticles are having a broad range of activity in the field for delivery of 
the anti-infective, anti-cancer and anti-inflammatory drugs. The nanoparticles 
are usually found in the range from 1 to 100 nm. The categories of nanoparticles 
include metals, solid lipid, micelles, liposome, polymers, dendrimers, and quantum 
dots [77–80]. The assembly of the nanoparticles are usually multilayered and the 
coatings of the nanoparticles are usually done to overcome the problems such as 
solubility, stability and specificity [81]. The issues related with the macromolecules 
such as low specificity, cell toxicity, high dose and cellular uptake can be limited by 
incorporating the drugs in the nanoparticles, even it have the ability to overcome 
the MDR related issues with P-gp and can enhance the therapeutic value of the 
parent drug [82].
8.25 Liposomes
Liposomes are extensively used for the delivery of the drugs which are impotent 
for the diffusion over the membrane layers. These can be modelled in phosphor 
lipid bi-layer and also in a micelle shapes which helps in encapsulating the soluble 
drugs and can hold on to their natural action. Thus nanoparticles mediate an appro-
priate activity in the management of MDR. For instant the activity of the Doxil 
encapsulated liposomal nanoparticles have the ability to manage the MDR part in 
the cancer cell lines [83].
8.26 Micelles
Micelles are the polymeric core-shell nanostructures with lypophilic drug core 
[84]. The lipophobic coating protects the lipophophilic drug from degradation 
and helps in its solubility. For this reason the lypophilic drugs have long circula-
tion in blood and also mediated the P-gp efflux. The Pharmacokinetic property 
of the drugs such as fexofenadine could be enhanced when formulated in a 
self-Nano emulsifying drug delivery system by hampering the CYP450 and P-gp 
mechanism.
8.27 Mesoporous silica nanoparticles
Mesoporous silica nanoparticles (MSNPS) are having larger pore size and pore 
volume, biocompatible in nature and are having high surface area. MSNPS have the 
capacity to load both anticancer drugs and siRNA together at the same time [85]. 
This combination can alter the resistance caused by P-gp and in turn can enhance 
the therapeutic efficacy of the drugs [86].
8.28 Polymeric nanoparticles
Polymers employed are usually natural (Gelatine, chitosan and albumin) or 
synthetic (poly [D, L-lactic acid], poly [D, L-lactic acid] and poly [ε-caprolactone]) 
in nature. The techniques [87] used for the preparation of polymeric nanoparticles 
are salting out, dialysis and microemulsion, interfacial polymerisation, supercriti-
cal fluid technique and solvent evaporation. Nanoparticles of Human albumin with 
abraxane and paclitaxel are formulated for improving the efficacy of metastatic 
breast and pancreatic cancer [88, 89]. This novel formulation is approved for clini-
cal studies by U.S. Food and drug administration.
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8.29 Expression and its over-expression, advantage and drawback
The expression of the P-gp is mainly found in all parts of the body by acting as 
a protective shield from the entry of the toxins and the xenobiotics. Their action 
is unavoidable in the Blood brain barrier, blood placental barrier and blood testes 
barrier but when concentration on the therapeutic aspect of the drugs the absorp-
tion of the drugs through the intestinal is retarded due to the expression of the 
P-gp in the intestinal lumen, not only in the lumen part though their presence are 
predicted all over the body but their expression is more in the diseased cells mainly 
the cancer cells. The plasma membrane of the intestinal epithelial cells pumps back 
the drug which enters into it and which are recognised as the substrate and are 
excreted [90–92]. Higher levels are seen in the biliary epithelium, proximal tubules 
of the kidney and the drugs are seen in the bile and the urine. For inhibiting the 
role of the P-gp the P-gp inhibitors are developed. Though the inhibitors shows the 
action when checked in preclinical studies but their action retards when come into 
the clinical trials. The progress report of the inhibitors are explained in Figure 1. 
The failure in the therapeutic efficacy with the cancer treatment is mainly due to the 
over-expression of P-gp.
8.30 Cancer and drug resistance
In 1940s: first cancer chemotherapy trails begin.
In 1970s: Mammalian cells showed resistance to the anticancer agents recur-
rently exhibited cross-resistance to drugs which are structurally and functionally 
dissimilar.
Multidrug resistance was a foremost problem in the cancer chemotherapy 
because it involved resistance to some of the commonly used and the first line 
anticancer drugs.
In 982s: Multidrug resistance was shown in most of the cases which results in 
decline in the intercellular drug accumulation, apparently as a result of altering in the 
plasma membrane. In many multidrug resistant cell lines, the resistance was found to 
correlate with over expression of a 170-kDa membrane protein (P-gp) [93, 94].
Why to study Multidrug resistance?
• Important role in the cancer multidrug resistance and its pathogenesis.
• Important role in Drug pharmacokinetics (Uptake distribution and excretion).
Figure 1. 
P-gp inhibitor development timeline. The progress report of the inhibitors.
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• Important role in removing toxins.
• Key role in development of inhibitors.
• To learn about the biology of the transport system.
9. Conclusion
P-gp is the protein belonging to the ABC family protein transporters with the 
aspect of protecting the cells and vital organs from the entry of the xenobiotics, 
toxins and drugs. The over-expression of the P-gp in the diseased cells leads to 
the therapeutic failure during the treatment regimen but the role of the P-gp for 
producing protective action in the brain and fetal cells are also unavoidable. Hence 
for an effective therapeutic aspect, the action of the P-gp and its role should be 
studied. For overcoming the unwanted action of the P-gp the inhibitors of the P-gp 
are mainly developed and the strategies for overcoming the MDR by using natural 
inhibitors and the formulation aspects and caused are mentioned in this chapter.
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